Hospital
Crawford Hospital District
Crawford Hospital District was paid $477K by Medicaid between Jan 2018 and Aug 2022, across 41 billing codes. Its largest line is 97110, Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion — 69% of everything it billed.
33Billing provider infoCRAWFORD HOSPITAL DISTRICT
ROBINSON, IL 62454
ROBINSON, IL 62454
33aNPI1164536645assigned 08/19/2006
33bProvider typeCritical Access Hospital
28Total paid$477K
24GClaims17,401
24DCodes billed41
24AFirst – last monthJan 2018 – Aug 2022
Compared with peers
Next to other Critical Access Hospital providers in Illinois
Rank by total paid#16 of 47
Median peer was paid$315K
This provider vs. median1.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 3,302 | $70K | |
| 2019 | 9,190 | $263K | |
| 2020 | 4,772 | $134K | |
| 2022 | 137 | $10K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 69% | 2,900 | 528 | $330K |
| 97161 | 3.7% | 112 | 73 | $18K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 3.5% | 665 | 561 | $17K |
| 84443 | Thyroid stimulating hormone (TSH) | 3.5% | 1,511 | 1,359 | $17K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 3.4% | 667 | 562 | $16K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.9% | 180 | 95 | $14K |
| 80053 | Comprehensive metabolic panel | 2.4% | 1,968 | 1,600 | $12K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.7% | 625 | 522 | $8K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 2,172 | 1,751 | $6K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 1.1% | 459 | 389 | $5K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 738 | 622 | $4K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 781 | 691 | $3K |
29 more codes
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 53 | $2K |
| 80061 | Lipid panel | <1% | 846 | $2K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 30 | $2K |
| 84439 | <1% | 485 | $2K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 14 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 279 | $2K |
| 84702 | <1% | 222 | $2K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 58 | $2K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 73 | $2K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 173 | $1K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 28 | $1K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 158 | $1K |
| 81001 | <1% | 882 | $1K | |
| 87186 | <1% | 167 | $1K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 83 | $1K |
| 85610 | <1% | 281 | $798.23 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 25 | $502.59 |
| 88142 | <1% | 157 | $350.62 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 13 | $326.20 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 28 | $247.14 |
| 87088 | <1% | 19 | $187.01 | |
| 87070 | <1% | 31 | $150.80 | |
| 85027 | <1% | 76 | $134.22 | |
| 82607 | <1% | 13 | $105.12 | |
| 83690 | <1% | 12 | $52.50 | |
| 82570 | <1% | 16 | $50.09 | |
| 83540 | <1% | 28 | $34.17 | |
| 83550 | <1% | 25 | $33.32 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 348 | $4.10 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANNIS, DONALD (CEO)